Tue, Feb 27, 2024
The share repurchase programme will close on March 6, 2024, the drug firm said in a regulatory filing.
More >
Mon, Dec 18, 2023
Zydus Lifesciences blasts through the roof, hitting a 52-week high after the US FDA greenlights a Phase II trial for its Parkinson's disease drug ZYIL1! This potential blockbuster medication targets a $2 billion market, setting Zydus on fire.
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.